IP83-09: Upfront perioperative enfortumab vedotin plus pembrolizumab versus risk-adapted adjuvant pembrolizumab or nivolumab: Cost-effectiveness analysis of emerging systemic therapies for cisplatin-ineligible patients with localized muscle-invasive bladd
Monday, May 18, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract